Clinical trials: Liver Diseases, Alcoholic
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Non-alcoholic Fatty Liver Disease
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
Investigate the methyl donors requirement of NAFLD patients to correct the malnutrition, lipid-toxicity, microbiota dysfunction, and metabolomics biomarkers.
- Trial name
- NCT05291104
- Testing
- Folic acid, choline chloride
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Fu Jen Catholic University Hospital
Non-Alcoholic Fatty Liver Disease
Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease
The purpose of this study is to pilot test a behavioral lifestyle intervention for Hispanic/Latino patients with non-alcoholic fatty liver disease (NAFLD)
- Trial name
- NCT05200585
- Testing
- Healthy Liver/Hígado Sano program, Usual standard of care
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The University of Texas Health Science Center, Houston
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease (NAFLD)
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate…
- Trial name
- NAFLD (NCT04330326)
- Testing
- Metabolic Cofactor Supplementation, Sorbitol
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- ScandiBio Therapeutics AB
Type2 Diabetes, NAFLD
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Non-Alcoholic Fatty Liver Disease( NAFLD) is common in patients with type 2 diabetes. Empagliflozin, an FDA-approved oral medication used to treat type 2 diabetes, has been shown to reduce production and deposition of fat in the…
- Trial name
- NCT02964715
- Testing
- Empagliflozin
- Where
- Malaysia
- Volunteers
- 25 people
- Sponsor
- University of Malaya
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Alcoholic Hepatitis
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
Alcoholic hepatitis is related to very high mortality rate. About 40% of the patients died within first 6 months after the detection of the clinical syndrome.
- Trial name
- NCT05840640
- Testing
- Standard Medical Therapy, G-CSF, G-CSF and NAC
- Where
- India
- Volunteers
- 66 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-alcoholic Fatty Liver Disease (NAFLD)
Exercise Dose and Nonalcoholic Fatty Liver Disease
The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people.
- Trial name
- ED (NCT00771108)
- Testing
- exercise
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Insulin Resistance, Non-Alcoholic Fatty Liver Disease
The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
The aim of this study is to investigate whether ingestion of curcumin will prevent hepatic insulin resistance (assessed by homeostatic model assessment of insulin resistance (HOMA-IR)) induced by short-term oral glucocorticoid…
- Trial name
- CURPRED (NCT04315350)
- Testing
- Curcumin Liposome, Prednisolone
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Alcohol Use, Unspecified
Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol…
- Trial name
- NCT03533660
- Testing
- Feedback, Enhanced Usual Care
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pittsburgh
Non Alcoholic Steatohepatitis
Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.
The aims of this study are as follows: To compare the role of alternate-day fasting over standard medical management alone to reverse NASH.
- Trial name
- NCT06676813
- Testing
- Alternate day fasting
- Where
- India
- Volunteers
- 72 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
- Trial name
- NCT04710524
- Testing
- FM101 150 mg BID, FM101 300 mg BID
- Where
- 12 sites in Hungary, Poland and 1 more
- Volunteers
- 60 people
- Sponsor
- Future Medicine
Non-alcoholic Fatty Liver Disease
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device…
- Trial name
- BEN (NCT02950610)
- Testing
- Breath analysis - electronic signature "Breath-print"
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Non Alcoholic Fatty Liver Disease
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
The purpose of the study is to evaluate the efficacy and safety of Niacinamide supplementation on clinical outcome of fatty liver patients having type II DM through measurement of the following before and after Niacinamide…
- Trial name
- NCT03850886
- Testing
- Niacinamide Oral Tablet, Antidiabetic
- Where
- Egypt
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Non Alcholic Fatty Liver Disease, Hepatic Steatosis
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease
- Conditions
- Non Alcholic Fatty Liver Disease, Hepatic Steatosis, Hepatic Fibrosis, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT06739486
- Volunteers
- 100 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease, Obesity
Alternate Day Fasting, Exercise, and NAFLD
Approximately 65% of obese individuals have non-alcoholic fatty liver disease (NAFLD), and this condition is strongly related to the development of insulin resistance and diabetes.
- Trial name
- NCT04004403
- Testing
- Alternate day fasting, Exercise
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease…
- Trial name
- LFQ (NCT04657523)
- Testing
- Investigational Liver Fat Quantification Software
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Cardiovascular Diseases, Fatty Liver
Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study
The P-SONAR study is a large, observational, prospective cohort study. The overall aim of the study is to investigate whether plaque burden estimation by 2D ultrasound of the carotid and femoral arteries may enhance…
- Conditions
- Cardiovascular Diseases, Fatty Liver, Atherosclerosis of Femoral Artery, Carotid Artery Plaque
- Trial name
- P-SONAR (NCT06933745)
- Where
- Norway
- Volunteers
- 21,029 people, healthy volunteers welcome
- Sponsor
- University Hospital, Akershus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.